Last reviewed · How we verify
SSRI
SSRI, marketed by the Baker Heart Research Institute, is a small molecule with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with a specific target in the body to produce a therapeutic effect, positioning it as a targeted treatment option. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | SSRI |
|---|---|
| Also known as | Lexapro, escitalopram, Prozac, fluoxetine, Sertraline |
| Sponsor | Baker Heart Research Institute |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder (NA)
- Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder (NA)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children (PHASE4)
- Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease (PHASE2)
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms (PHASE3)
- A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
- Effect of Virtual Reality on Depression in Adolescent Females (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSRI CI brief — competitive landscape report
- SSRI updates RSS · CI watch RSS
- Baker Heart Research Institute portfolio CI